A strategy to enhance bioavailability of drug candidates: Natural Bioenhancers

Main Article Content

Nishat Ara
Thaiseen Sultana
Rajesh Bolleddu
Dr. Sama Venkatesh
A Ravi Kiran

Abstract

Nowadays herbs are increasingly being used worldwide as therapeutic agents or in collaboration with minerals and vitamins in health supplements, teas etc. There are many advantages of herbalism over modern or conventional medicine such as the herbal/traditional systems of medicine causes lesser side effects than modern medicine; herbal medicine along with lifestyle modification enhances its potency by assisting and boosting the inborn self-healing mechanisms of the patient. Thus, the chronic disorder is not only cured but the possibilities of its recurrence are highly reduced. However, despite having great in-vitro potential, herbs or herbal extracts have demonstrated very less in-vivo activity due to insufficient lipid solubility and irregular molecular size. Thus, this led to poor absorption and poor bioavailability. With the advancement in science and technology, several trials are undergone to enhance the bioavailability of drugs via novel drug delivery systems such as microspheres, nanoparticles, liposomes, transferosomes, lipid-based systems, etc. Besides these novel approaches, there are certain compounds that exist in nature that are found to exhibit enhanced bioavailability rate such as piperine, curcumin, naringin, quercetin, genistein, etc. The objective of this review is to throw light on bioavailability enhancing effects of these natural bioenhancers of herbal origin, their characteristic features and mechanisms of action.

Article Details

How to Cite
Nishat Ara, Thaiseen Sultana, Bolleddu, R., Dr. Sama Venkatesh, & A Ravi Kiran. (2021). A strategy to enhance bioavailability of drug candidates: Natural Bioenhancers. International Journal of Pharmaceutical and Bio Medical Science, 1(1), 10–14. Retrieved from http://ijpbms.com/index.php/ijpbms/article/view/8
Section
Articles

References

Acharya SN, Parihar VG, Acharya RS. Phytosomes: Novel approach for delivering herbal extract with improved bioavailability. Int J Pharm Sci 2011; 2:144-160.

Manach C, Scalbert A and Morand C. Polyphenols: Food sources and bioavailability. Am. J. Clin. Nutr 2004; 79:727-47.

Brahmankar DB, Jaiswal S. Biopharmaceutics and Pharmacokinetics: A treatise. Edn 1, VallabhPrakashan, 1995, 24-26.

Drabu S, Khatri S, Babu S, Lohani P. Use of herbal bioenhancers to increase the bioavailability of drugs. RJPBCS 2011;2(4):108-119

Patil UM, Singh A, Chakraborty AK. Role of piperine as a bioavailability enhancer. International Journal of Recent Advances in Pharmaceutical Research 2011;1 (4):16-23.

Jhanwar B, Gupta S. Biopotentiation using herbs: Novel technique for poor bioavailable drugs. Int J Pharm Tech Res. 2014; 6(2):443-454.

Kesarwani K, Gupta R. Bioavailabilty enhancers of herbal origin: An overview. Asian Pac. J. Trop. Biomed. 2013;3(4):253-266.

Muttepawar SS, Jadhav SB, Kankudate Ad, Sanghai SD, Usturge DR, Chavare SS. A review on Bioavailabilty enhancers of herbal origin. World J. Pharm. Pharm. Sci. 2014;3(3):667-677.

Jain G, Patil UK. Strategies for enhancement of Bioavailability of Medicinal Agents. Int. J. Pharm. Sci Res. 2015;6(12):5315-5324.

Hayton WL. J. Pharmacokinet Pharmacodyn. 1989; 8:1573-8744

Myung Joo Kang, Jae Youl Cho, ByungHo Shim, Duk Ki Kim, Jaehwi Lee. Bioavailability enhancing activities of natural compounds from medicinal plants. J Med Plants Res. 2009;3(13): 1204-1211.

Tatiraju DV, Bagade VB, Karambelkar PJ, Jadhav VM, Kadam V. Natural Bioenhancers: An overview. J. Pharmacogn. Phytochem. 2013;2(23):55-60.

Tatiraju DV, Bagade VB, Karambelkar PJ, Jadhav VM, Kadam V. Natural Bioenhancers: An overview. J. Pharmacogn. Phytochem. 2013;2(23):55-60.

Srivalli KMR, Lakshmi PK. Overview of P-glycoprotein inhibitors: A rational outlook. Braz J Pharm Sci. 2012;48(3):353–67.

Varma MVS, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharmacol Res. 2003;48(4):347–59.

Shapiro AB, Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. BiochemPharmacol. 1997;53(4): 587–96.

Drori S, Eytan GD, Assaraf YG. Potentiation of anticancer drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem. 1995;228(3):1020–9.

Robert J, Jarry C. Multidrug resistance reversal agents. J Med Chem. 2003;46(23):4805–17.

Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic: A vision for applied use. BiochemPharmacol. 2006; 71(7):910–8.

Pusztai L, Wagner P, Ibrahim N, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005;104(4):682–91.

Thomas H, Coley HM. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003; 10(2):159–65.

Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000;11(4):265–83.

Newman MJ, Rodarte JC, Benbatoul KD, et al. Discovery and characterization of OC144–093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 2000;60(11):2964–72.

Lomovskaya O, Zgurskaya HI, Totrov M, Watkins WJ. Waltzing transporters and ‘the dance macabre’ between humans and bacteria. Nat Rev Drug Discov. 2007;6(1):56–65.

Kuppens IE, Witteveen EO, Jewell RC, et al. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res. 2007;13(11): 3276–85.

Malingré MM, Beijnen JH, Rosing H, et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer. 2001;84(1):42–7.

Liu MZ, Zhang YL, Zeng MZ, He FZ, Luo ZY, Luo JQ, et al. Pharmacogenomics and herb-drug interactions: merge of future and tradition. Evid Based Compl Alt Med. (2015) 2015:1–8. doi: 10.1155/2015/32109.

Teo YL, Ho HK, Chan A. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: Current understanding, challenges and recommendations. Br J Clin Pharm. (2015) 79:241–53. doi: 10.1111/bcp.12496.

Kumar S, Sharma R, Roychowdhury A. Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: A medicinal chemistry perspective. Cur Med Chem. (2012) 19:3605–21.

doi: 10.2174/092986712801323180.